| Entry |
|
|---|
| Name |
Lamivudine (JAN/USP/INN);
Epivir (TN) |
|---|
| Abbr |
3TC |
|---|
| Product |
|
|---|
| Generic |
LAMIVUDINE (American Health Packaging), LAMIVUDINE (Apotex Corp.), LAMIVUDINE (Apotex Corp.), LAMIVUDINE (Aurobindo Pharma Limited), LAMIVUDINE (Aurobindo Pharma Limited), LAMIVUDINE (Camber Pharmaceuticals), LAMIVUDINE (Camber Pharmaceuticals), LAMIVUDINE (Camber Pharmaceuticals), LAMIVUDINE (Chartwell RX), LAMIVUDINE (Cipla USA), LAMIVUDINE (Golden State Medical Supply), LAMIVUDINE (Ingenus Pharmaceuticals), LAMIVUDINE (Lannett Company), LAMIVUDINE (Lupin Pharmaceuticals), LAMIVUDINE (Macleods Pharmaceuticals Limited), LAMIVUDINE (Major Pharmaceuticals), LAMIVUDINE (Prasco Laboratories), LAMIVUDINE (Rising Health), LAMIVUDINE (Strides Pharma Science Limited) |
|---|
| Formula |
C8H11N3O3S
|
|---|
| Exact mass |
229.0521
|
|---|
| Mol weight |
229.2562
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antiviral
DG01890 Nucleoside reverse transcriptase inhibitor (NRTI)
DG03107 Anti-HIV agent
DG01656 HIV reverse transcriptase inhibitor
Transporter substrate
DG02859 SLC22A6 substrate
|
|---|
| Remark |
| Therapeutic category: | 6250 |
|
|---|
| Efficacy |
Antiviral, Reverse transcriptase inhibitor |
|---|
| Disease |
|
|---|
| Target |
HBV reverse transcriptase [KO: K21037] HIV-1 reverse transcriptase [KO: K24802] |
|---|
| Pathway |
|
|---|
| Metabolism |
Transporter: SLC22A6 [HSA: 9356]
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Other map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AF Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF05 Lamivudine
D00353 Lamivudine (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-hepatitis B (HBV) Agents
Lamivudine
D00353 Lamivudine (JAN/USP/INN)
Anti-HIV Agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTI)
Lamivudine
D00353 Lamivudine (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D00353 Lamivudine (JAN/USP/INN)
Drug groups [BR:br08330]
Antiviral
DG01890 Nucleoside reverse transcriptase inhibitor (NRTI)
D00353 Lamivudine
DG03107 Anti-HIV agent
DG01656 HIV reverse transcriptase inhibitor
D00353 Lamivudine
Transporter substrate
DG02859 SLC22A6 substrate
D00353 Lamivudine
Drug classes [BR:br08332]
Antiviral
DG03107 Anti-HIV agent
D00353 Lamivudine
Antimicrobials [BR:br08307]
Antivirals
Genome replication inhibitor
HBV reverse transcriptase inhibitor
D00353 Lamivudine (JAN/USP/INN) <JP/US>
Antimicrobials abbreviations [BR:br08327]
Antivirals
Genome replication inhibitor
HBV reverse transcriptase inhibitor
D00353 Lamivudine (JAN/USP/INN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00353
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00353
Drug metabolizing enzymes and transporters [br08309.html]
Drug transporters
D00353
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 15
1 C1y C 19.1100 -17.9200
2 O2x O 17.9900 -17.0800
3 C1x C 18.6900 -19.2500
4 C1y C 16.8700 -17.9200
5 S2x S 17.2900 -19.2500
6 C1b C 15.6800 -17.2900
7 O1a O 14.3500 -18.1300
8 C8x C 20.3000 -15.8200
9 N4y N 20.3000 -17.2200
10 C8y C 21.4900 -17.9200
11 N5x N 22.7500 -17.2200
12 C8y C 22.7500 -15.8200
13 C8x C 21.4900 -15.1200
14 O5x O 21.4900 -19.3200
15 N1a N 23.9400 -15.1200
BOND 16
1 1 2 1
2 1 3 1
3 2 4 1
4 3 5 1
5 4 6 1 #Down
6 6 7 1
7 4 5 1
8 8 9 1
9 9 10 1
10 10 11 1
11 11 12 2
12 12 13 1
13 8 13 2
14 1 9 1 #Down
15 10 14 2
16 12 15 1
|
|---|
